Patient clinical characteristics
| . | Patients . | |||
|---|---|---|---|---|
| . | B-ALL (n = 99) . | T-ALL (n = 27) . | ||
| . | n . | % . | n . | % . |
| Sex | ||||
| Male | 43 | 43.4 | 21 | 77.8 |
| Female | 56 | 56.6 | 6 | 22.2 |
| Age, y | ||||
| <1 | 4 | 4.0 | 0 | 0.0 |
| 1-9.99 | 77 | 77.8 | 19 | 70.4 |
| ≥10 | 18 | 18.2 | 8 | 29.6 |
| WBC, ×109/L | ||||
| <50 | 84 | 84.8 | 11 | 40.7 |
| ≥50 | 15 | 15.2 | 16 | 59.3 |
| NCI risk | ||||
| Standard | 62 | 62.6 | — | — |
| High | 37 | 37.4 | — | — |
| Extramedullary disease | 12 | 12.1 | 3 | 11.1 |
| Trisomy 21 | 5 | 5.1 | 0 | 0.0 |
| WHO subtype classification* | ||||
| Defined | ||||
| Hyperdiploid | 29 | 29.3 | — | — |
| Hypodiploid | 5 | 5.0 | — | — |
| BCR-ABL1 | 4 | 4.0 | — | — |
| KMT2A-rearranged | 6 | 6.1 | — | — |
| ETV6-RUNX1 | 20 | 20.2 | — | — |
| TCF3-PBX1 | 2 | 2.0 | — | — |
| IL3-IGH | 1 | 1.0 | — | — |
| Provisional entities | ||||
| Early T-cell precursor ALL | — | — | 4 | 14.8 |
| Undefined | 32 | 32.3 | 23 | 85.2 |
| MRD status at the end of induction† | ||||
| Positive | 35 | 35.4 | 18 | 66.7 |
| Negative | 64 | 64.6 | 9 | 33.3 |
| MRD status at the end of consolidation† | ||||
| Positive | 8 | 8.1 | 9 | 33.3 |
| Negative | 91 | 91.9 | 18 | 66.7 |
| Bone marrow transplantation | ||||
| Total number of patients | 11 | 11.1 | 6 | 22.2 |
| CR1 | 3 | 3.0 | 6 | 22.2 |
| CR2 | 8 | 8.1 | 1 | 3.7 |
| Outcome | ||||
| Death | 9 | 9.1 | 0 | 0.0 |
| Relapse | 16 | 16.2 | 1 | 3.7 |
| No event | 79 | 79.8 | 26 | 96.3 |
| . | Patients . | |||
|---|---|---|---|---|
| . | B-ALL (n = 99) . | T-ALL (n = 27) . | ||
| . | n . | % . | n . | % . |
| Sex | ||||
| Male | 43 | 43.4 | 21 | 77.8 |
| Female | 56 | 56.6 | 6 | 22.2 |
| Age, y | ||||
| <1 | 4 | 4.0 | 0 | 0.0 |
| 1-9.99 | 77 | 77.8 | 19 | 70.4 |
| ≥10 | 18 | 18.2 | 8 | 29.6 |
| WBC, ×109/L | ||||
| <50 | 84 | 84.8 | 11 | 40.7 |
| ≥50 | 15 | 15.2 | 16 | 59.3 |
| NCI risk | ||||
| Standard | 62 | 62.6 | — | — |
| High | 37 | 37.4 | — | — |
| Extramedullary disease | 12 | 12.1 | 3 | 11.1 |
| Trisomy 21 | 5 | 5.1 | 0 | 0.0 |
| WHO subtype classification* | ||||
| Defined | ||||
| Hyperdiploid | 29 | 29.3 | — | — |
| Hypodiploid | 5 | 5.0 | — | — |
| BCR-ABL1 | 4 | 4.0 | — | — |
| KMT2A-rearranged | 6 | 6.1 | — | — |
| ETV6-RUNX1 | 20 | 20.2 | — | — |
| TCF3-PBX1 | 2 | 2.0 | — | — |
| IL3-IGH | 1 | 1.0 | — | — |
| Provisional entities | ||||
| Early T-cell precursor ALL | — | — | 4 | 14.8 |
| Undefined | 32 | 32.3 | 23 | 85.2 |
| MRD status at the end of induction† | ||||
| Positive | 35 | 35.4 | 18 | 66.7 |
| Negative | 64 | 64.6 | 9 | 33.3 |
| MRD status at the end of consolidation† | ||||
| Positive | 8 | 8.1 | 9 | 33.3 |
| Negative | 91 | 91.9 | 18 | 66.7 |
| Bone marrow transplantation | ||||
| Total number of patients | 11 | 11.1 | 6 | 22.2 |
| CR1 | 3 | 3.0 | 6 | 22.2 |
| CR2 | 8 | 8.1 | 1 | 3.7 |
| Outcome | ||||
| Death | 9 | 9.1 | 0 | 0.0 |
| Relapse | 16 | 16.2 | 1 | 3.7 |
| No event | 79 | 79.8 | 26 | 96.3 |
CR1/CR2, complete remission-1 and -2.
WHO subtype classification based on karyotype and FISH analysis performed as part of standard clinical diagnostic testing.
MRD positive defined as ≥0.01% leukemic cells measured by flow cytometry. Where flow cytometry was uninformative, quantitative real-time PCR and molecular markers were used to determine MRD status.